Due to the frequent rejection of claims for noninvasive ventilators by Medicare Advantage plans, individuals with amyotrophic lateral sclerosis (ALS) are experiencing disproportionately high rates of hospital admissions.
Due to the frequent rejection of claims for noninvasive ventilators (NIVs) by Medicare Advantage plans, individuals with amyotrophic lateral sclerosis (ALS) are experiencing disproportionately high rates of hospital admissions for inpatient care. Jeffrey Sippel, MD, MPH, associate director of inpatient clinical services and associate professor of clinical medicine in the Pulmonary Sciences & Critical Care Medicine Division at the University of Colorado School of Medicine, highlighted this issue in an interview with the American Journal of Managed CareⓇ (AJMCⓇ).
Transcript
What has been the impact of these denials on patients with ALS and their families, considering the urgency of their medical needs?
I think the impact of this type of approach from the insurance companies, I think it's had a huge impact on our patients and the families. What we like to do is provide relatively seamless care for these very, very complex patients. Here's how I would define seamless care: Three to 5 to 6 years ago, if we had a patient who had imminent need for support, we could actually get it arranged within 24 hours. There are even times where we saw a patient on Friday and had support arranged for them at home by Saturday. That is super cool, and it is super good.
And so when you have that as what's achievable, and what's doable, and then you fall back to having to wait days to weeks or longer, secondary to denials and appeals, then the most important thing is that it delays life-saving care for these patients, number 1. Number 2, we sometimes have to admit them to the hospital, which is a big wildcard and it's a big disruption for them. And then number 3, the family and the support. They want these patients at home, they want to love the heck out of them. And when there are delays in care and they watch their loved one going downhill without support or have to get admitted to the hospital, that's just a really complicated thing. Unfortunately, a lose-lose is really what it's been on this.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More